Clinical trials
Phase 2/3 Lymphoma, Follicular trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
15 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2002 | 1 |
| 2004 | 1 |
| 2013 | 1 |
| 2015 | 1 |
| 2016 | 2 |
| 2020 | 2 |
| 2021 | 1 |
| 2024 | 1 |
| 2025 | 1 |
| 2026 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 6 |
| Unknown status | 3 |
| Recruiting | 2 |
| Terminated | 2 |
| Active, not recruiting | 1 |
| Withdrawn | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Actinogen Medical | 1 |
| Assiut University | 1 |
| Chiron Corporation | 1 |
| Gavin Bart | 1 |
| Gilead Sciences | 1 |
| Great Ormond Street Hospital for Children NHS Foundation Trust | 1 |
| Haruhiko Fukuda | 1 |
| Health Institutes of Turkey | 1 |
| Medical College of Wisconsin | 1 |
| Merck Sharp & Dohme LLC | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Lymphoma, Follicular | 15 |
| Lymphoma, Non-Hodgkin | 5 |
| Lymphoma, Large B-Cell, Diffuse | 4 |
| Burkitt Lymphoma | 3 |
| Leukemia, Lymphocytic, Chronic, B-Cell | 3 |
| Lymphoma, B-Cell, Marginal Zone | 3 |
| Lymphoma, Mantle-Cell | 3 |
| COVID-19 | 2 |
| Lymphoma | 2 |
| Lymphoma, Large-Cell, Immunoblastic | 2 |
Trials
Showing 51 to 15 of 15. Each trial links to its page on Pharma Observatory.
No trials match these filters.
Try a different keyword, or clear a filter.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.